Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Enhanced Post-licensure Safety Surveillance Study of the Combined Tetanus, Diphtheria (Reduced Dose) and Recombinant Acellular Pertussis Vaccine (TdaP), Boostagen®, in Thailand

NCT07444502 is registered in ClinicalTrials.gov with BioNet-Asia Co., Ltd. as lead sponsor.

NCT NCT07444502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07444502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Enhanced Post-licensure Safety Surveillance Study of the Combined Tetanus, Diphtheria (Reduced Dose) and Recombinant Acellular Pertussis Vaccine (TdaP), Boostagen®, in Thailand
Lead sponsor
BioNet-Asia Co., Ltd.
Phase
Observational
Overall status
Completed
Start date
June 30, 2017
Completion date
March 27, 2023
Enrollment
10,727 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, pertussis (whooping cough), tetanus